The Key Laboratory of Bio-Medical Diagnostics, Suzhou Institute of Biomedical Engineering and Technology (SIBET), Chinese Academy of Sciences, Suzhou, China.
Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, No. 88 Keling Road, Suzhou New District, Suzhou, China.
Medicine (Baltimore). 2021 Oct 29;100(43):e27586. doi: 10.1097/MD.0000000000027586.
Corona virus disease 2019 (COVID-19) is spreading fast and it brings great pressure to the social economy. Many reports revealed that ginseng can develop immunity for respiratory disease, but there is no evidence to prove its effects on COVID-19. This protocol of systematic review and meta-analysis will clarify the safety and effectiveness of ginseng adjuvant therapy on COVID-19 patients.
Different databases (Web of Science, Cochrane Library, PubMed, Chinese Biomedical Literature Database, Chinese National Knowledge Infrastructure, Chinese Scientific Journal Database, Wan fang Database, ClinicalTrials, World Health Organization Trials, and Chinese Clinical Trial Registry) will be retrieved to search related articles according to pre-defined inclusion and exclusion criteria. Clinical recovery time and effective rates will be assessed as the primary outcomes and any changes of patient's condition will be considered as the secondary outcomes. Subgroup analysis and sensitivity analysis will be conducted to explore sources of heterogeneity. Endnote X9.3 will be used to manage data screening. The statistical analysis will be completed by RevMan5.3 and Stata/SE 15.1 software.
This study will assess the effects and safety for ginseng adjuvant therapy on COVID-19 patients.
The discussion will be considered to determine whether sufficient evidence exists to prove the effects of ginseng adjuvant therapy for COVID-19 patients.
PROSPERO (ID: CRD42021277843).
2019 年冠状病毒病（COVID-19）传播迅速，给社会经济带来巨大压力。许多报道显示，人参可以增强呼吸道疾病的免疫力，但尚无证据证明其对 COVID-19 的疗效。本系统评价和荟萃分析的方案旨在阐明人参辅助治疗 COVID-19 患者的安全性和有效性。
根据预先设定的纳入和排除标准，检索不同的数据库（Web of Science、Cochrane Library、PubMed、中国生物医学文献数据库、中国国家知识基础设施、中国科学期刊数据库、万方数据库、ClinicalTrials、世界卫生组织临床试验和中国临床试验注册中心），以搜索相关文章。临床康复时间和有效率将作为主要结局进行评估，患者病情的任何变化将作为次要结局进行评估。将进行亚组分析和敏感性分析，以探索异质性的来源。Endnote X9.3 将用于管理数据筛选。统计分析将由 RevMan5.3 和 Stata/SE 15.1 软件完成。
本研究将评估人参辅助治疗 COVID-19 患者的效果和安全性。
将进行讨论，以确定是否有足够的证据证明人参辅助治疗 COVID-19 患者的疗效。
PROSPERO（ID：CRD42021277843）。
